Oct 06, 2019 among the 209 patients receiving mekinist plus dabrafenib, 26% were exposed to mekinist for 6 months to 12 months while 46% were exposed to mekinist for 1 year. Tafinlar is indicated, in combination with trametinib, for the treatment of patients with metastatic nonsmall cell lung cancer nsclc with braf v600e mutation. Refer to the dabrafenib prescribing information for. The european medicines agency decided that tafinlars benefits in cancers that carry the braf v600 mutation are greater than its risks and it can be authorised for use in the eu. It is used either on its own or in combination with another medicine containing dabrafenib to. Mekinist will be approved based on the following criterion. Highlights of prescribing information these highlights do not include all the information needed to use feraheme safely and effectively. Mekinist is a medicine that contains the active substance trametinib. Assess left ventricular ejection fraction before treatment with tafinlar and mekinist, after 1 month of treatment, then every 2 to 3 months thereafter. If improved within 4 weeks, resume mekinist at a lower dose reduced by 0. Your healthcare provider should do a blood test to check your levels of cpk before and during treatment. Refer to the dabrafenib prescribing information for recommended dabrafenib dosing information.
Mekinist is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test. Product monograph for important warnings and precautions for dabrafenib in. Highlights of prescribing information perforation can. Mekinist is indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fda approved test.
Check your skin and tell your health care provider right away about any. Highlights of prescribing information these highlights do not include all the information needed to use gleevec safely and effectively. This leaflet is part iii of a threepart product monograph. Highlights of prescribing information these highlights do. Stivarga regorafenib can cause liver problems, which can be serious and sometimes lead to death. Braf testing for melanoma kinase inhibitor responses evicore. The agency considered that tafinlar when used alone or in combination with trametinib had shown clinically relevant benefit in patients with advanced nonsmall cell.
Highlights of prescribing information venous thromboembolism. Trametinib is an oral small molecule kinase inhibitor of mitogenactivated extracellular signal regulated kinase 1 and. Tafinlar is used in combination with trametinib mekinist and either cetuximab or panitumumab 2. Arterial occlusion has occurred in at least 35% of iclusig treated patients including fatal myocardial infarction, stroke, stenosis of large arterial. Infusion reactions and cardiopulmonary arrest 1 indications and usage 1. Administer feraheme as an intravenous infusion in 50200 ml 0. Mekinist will be approved based on all of the following criteria. Idhifa for relapsed refractory acute myeloid leukemia. If you have difficulty viewing the document below, please click here to view the full prescribing information, including the boxed warning. The recommended dosage regimen of mekinist is 2 mg orally once daily.
As the impact of nintedanib on the effectiveness of hormonal contraception is unknown, advise women using hormonal contraceptives to add a barrier method. Mekinist as a single agent is indicated for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fdaapproved. Use caution when treating patients at higher cardiovascular risk including known coronary. Stivarga regorafenib is a prescription medicine used to treat people with. Take mekinist at least 1 hour before or at least 2 hours after a meal. Highlights of prescribing information urothelial carcinoma. These highlights do not include all the information needed to use. Zelboraf is not used to treat melanoma with a normal braf gene. Cardiomyopathy, including cardiac failure, can occur. The recommended dose of feraheme is an initial 510 mg dose followed by a second 510 mg dose 3 to 8 days later.
Monitor patients receiving cotellic, when administer ed with vemurafenib, for signs or symptoms of noncutaneous malignancies. Specialty guideline management mekinist trametinib policy i. Mekinist reference guide for safe and effective use from the american society of healthsystem pharmacists ahfs di. Easy to read fda package insert, drug facts, dosage and administration, and adverse effects for arimidex anastrozole. Tafinlar dabrafenib capsules and mekinist trametinib tablets are prescription medicines that can be used in combination to treat people with a type of skin cancer called melanoma. Initiate treatment with letairis in females of reproductive potential only after a negative pregnancy test. Highlights of prescribing information cardiomyopathy. In the combid study, adverse reactions leading to discontinuation of mekinist occurred in 11% of patients receiving mekinist plus dabrafenib. Mulpleta is a thrombopoietin receptor agonist for the treatment of thrombocytopenia in. Your healthcare provider will do blood tests to check your liver function. In clinical trials at recommended doses, obtundation and clinically significant respiratory depression occurred in adult patients treated with xyrem see warnings and precautions 5. Mekinist trametinib, in combination with dabrafenib, is indicated for the adjuvant treatment of patients with melanoma with a braf v600. Mekinist is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fdaapproved test, and involvement of lymph nodes, following complete resection.
Mekinist in combination with dabrafenib is not recommended in patients who have. Care and management of unique toxicities associated with mapk pathwaytargeted therapies in patients with advanced melanoma. Highlights of prescribing information tafinlar with. Additionally, mekinist in combination with dabrafenib is used to treat patients with metastatic nonsmall cell.
Vemurafenib zelboraf, dabrafenib tafinlar, and trametinib mekinist are. Withhold mekinist for uncomplicated dvt and pe for up to 3 weeks. Dec 01, 2018 zelboraf is a prescription medicine used to treat. Zelboraf fda prescribing information, side effects and uses. Dabrafenib as monotherapy or in combination with trametinib is indicated for the. Trametinib dimethyl sulfoxide is a kinase inhibitor. Dabrafenib tafinlar, novartis pharmaceuticals corp.
Asymptomatic, absolute decrease in lvef of 10% or greater from baseline and is below lln that improves to normal lvef value within 4 weeks following interruption of mekinist. Tafinlar, when used in combination with mekinist, may cause a. Tafinlar, when used in combination with mekinist, may cause a type of skin cancer called cutaneous squamous cell carcinoma, keratoacanthoma, basal cell carcinoma, or melanoma. Dabrafenibtrametinib combination therapy for melanoma. Mekinist is not indicated for the treatment of patients who have received prior braf inhibitor therapy. Mekinist trametinib rationale for inclusion in pa program. Trametinib dimethyl sulfoxide is a white to almost white powder. Authorization of 12 months may be granted for adjuvant treatment of cutaneous melanoma with a braf v600 activating mutation in combination with trametinib. The first fdaapproved ivd for braf v600e and v600k mutation detection in metastic melanoma.
See full prescribing information for complete boxed warning. Tafinlar, in combination with mekinist, is indicated for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fdaapproved test, and involvement of lymph node s, following complete resection. The thxidbraf kit is an in vitro diagnostic device intended for the qualitative detection of the braf v600e and v600k mutations in dna samples extracted from formalinfixed paraffinembedded ffpe human melanoma tissue. That has spread to other parts of the body metastatic or cannot be removed by surgery unresectable, and. Highlights of prescribing information perforation can occur. Cometriq is indicated for the treatment of patients with progressive, metastatic medullary. Treatment with cotellic may increase the level of an enzyme in your blood called creatine phosphokinase cpk and may be a sign of muscle damage.
Similar safety and efficacy of once and twicedaily. Mekinist is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test. Specialty guideline management tafinlar dabrafenib policy. Authorization of 12 months may be granted for treatment of brain metastases from melanoma with a braf v600 activating mutation in combination with trametinib mekinist. Talk with your health care provider about your risk for these cancers. Dabrafenib is a selective kinase inhibitor that is active against several mutated forms of braf kinase including braf v600e, braf v600k, and braf v600d. The printed package leaflet of the medicinal product must state the name and. Tafinlar is not indicated for the treatment of patients with wildtype braf melanoma. The recommended dosage of mekinist is 2 mg orally taken once daily in combination with dabrafenib until disease recurrence or unacceptable toxicity. Prior authorization is required to ensure the safe, clinically appropriate and costeffective use of mekinist while maintaining optimal therapeutic outcomes.
293 555 800 207 1027 1491 683 288 494 347 60 274 1211 1369 1157 326 545 1206 877 1574 1341 1500 1416 877 1367 1509 1276 1097 69 879 836 104 252